Why Danaher (DHR) Stock Rose Today

Danaher Corporation (DHR) is up 4.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be tied to investor optimism around Danaher’s recently completed Masimo acquisition, along with continued confidence in its improving 2026 outlook. There does not appear to be a major fresh company-specific announcement today beyond the recently scheduled July 21 earnings call, so the rally may reflect a continued re-rating after recent strategic and operating updates.

Details:

Danaher completed its acquisition of Masimo on June 10, adding patient-monitoring and pulse oximetry assets to its diagnostics portfolio.

When Danaher announced the deal, it said Masimo was expected to generate more than $530 million of EBITDA in 2027, with over $125 million of annual cost synergies and more than $50 million of annual revenue synergies by the fifth full year after closing.

In first-quarter 2026 results, Danaher posted 9.5% adjusted EPS growth, said revenue rose 3.5%, and lifted the high end of its full-year adjusted EPS guidance.

Danaher also just scheduled its second-quarter 2026 earnings call for July 21, which may be reinforcing expectations for more color on integration progress and end-market demand.

Sources:

Danaher Investor Relations, SEC, MedTech Dive, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DHR Insider Trading Activity

$DHR insiders have traded $DHR stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:

GREGORY M MILOSEVICH (Executive Vice President) sold 1,320 shares for an estimated $274,574
ALAN G SPOON sold 1,358 shares for an estimated $237,206

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive DHR Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$DHR Hedge Fund Activity

We have seen 935 institutional investors add shares of $DHR stock to their portfolio, and 1,258 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL RESEARCH GLOBAL INVESTORS added 8,322,198 shares (+1445.9%) to their portfolio in Q1 2026, for an estimated $1,556,583,913
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 5,739,048 shares (-87.3%) from their portfolio in Q4 2025, for an estimated $1,313,782,868
CAPITAL INTERNATIONAL INVESTORS removed 4,231,295 shares (-23.2%) from their portfolio in Q1 2026, for an estimated $791,421,416
HOLOCENE ADVISORS, LP added 3,099,516 shares (+329.9%) to their portfolio in Q1 2026, for an estimated $579,733,472
FMR LLC added 3,027,600 shares (+15.5%) to their portfolio in Q1 2026, for an estimated $566,282,304
JPMORGAN CHASE & CO added 2,943,496 shares (+15.8%) to their portfolio in Q4 2025, for an estimated $673,825,104
VIKING GLOBAL INVESTORS LP removed 2,751,245 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $629,815,005

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DHR Government Contracts

We have seen $131,468,924 of award payments to $DHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

IN-VITRO REAGENTS - VISN 15, ORDERING PERIOD ONE: $2,952,609
MICROBIOLOGY REAGENTS & CONSUMABLES ADD CLAUSE 852.222-71 - COMPLIANCE WITH EXECUTIVE ORDER 13899: $2,353,640
MRSA REAGENTS: $1,655,465

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$DHR Analyst Ratings

Wall Street analysts have issued reports on $DHR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 01/29/2026
Jefferies issued a "Buy" rating on 01/29/2026

To track analyst ratings and price targets for $DHR, check out Quiver Quantitative's $DHR forecast page.

$DHR Price Targets

Multiple analysts have issued price targets for $DHR recently. We have seen 15 analysts offer price targets for $DHR in the last 6 months, with a median target of $230.0.

Here are some recent targets:

David Westenberg from Piper Sandler set a target price of $200.0 on 06/11/2026
Rajesh Kumar from HSBC set a target price of $230.0 on 06/03/2026
Patrick Donnelly from Citigroup set a target price of $95.0 on 05/27/2026
Dan Leonard from RBC Capital set a target price of $200.0 on 05/15/2026
Kallum Titchmarsh from Morgan Stanley set a target price of $255.0 on 04/23/2026
Brandon Couillard from Wells Fargo set a target price of $212.0 on 04/22/2026
Dan Leonard from UBS set a target price of $250.0 on 04/22/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.